The splicing mutation 3272-26AϾG is widespread in Eu- at intron 17a, because this product contains premature stop Mutations affecting the splicing of the cystic fibrosis (CF) codon (5), and CFTR mRNA lacking exon 9, a common transmembrane conductance regulator (CFTR) gene that event which occurs in variable levels both in CF and non-CF lead to the simultaneous presence of correctly and aberinvividuals (6). Furthermore, the level of normally spliced rantly spliced transcripts (included in class I [1], previously CFTR transcripts had to be corrected for the reduced abunclass V) cause CF disease due to insufficient levels of the dance of CFTR transcripts bearing the F508del mutation normal mRNA, and hence, functional protein. Previous when compared with wild-type (wt) transcripts. After incorstudies have reported a wide range of normal CFTR tranporating a rigorous control for polymerase chain reaction scripts, from less than 4% (2) to less than 20%, associated (PCR) amplification efficiency (see Figure 1 ), we achieved with "leaky" splicing mutations (3). However, it is important consistent and reproducible results on five patients with to obtain reliable data on this issue for the design of theraidentical CFTR genotypes. pies aiming at restoring lung function by increasing the levels of normal CFTR, namely gene therapy.
sulting in a transcript with 25 extra nucleotides and a prema- at intron 17a, because this product contains premature stop Mutations affecting the splicing of the cystic fibrosis (CF) codon (5), and CFTR mRNA lacking exon 9, a common transmembrane conductance regulator (CFTR) gene that event which occurs in variable levels both in CF and non-CF lead to the simultaneous presence of correctly and aberinvividuals (6). Furthermore, the level of normally spliced rantly spliced transcripts (included in class I [1], previously CFTR transcripts had to be corrected for the reduced abunclass V) cause CF disease due to insufficient levels of the dance of CFTR transcripts bearing the F508del mutation normal mRNA, and hence, functional protein. Previous when compared with wild-type (wt) transcripts. After incorstudies have reported a wide range of normal CFTR tranporating a rigorous control for polymerase chain reaction scripts, from less than 4% (2) to less than 20%, associated (PCR) amplification efficiency (see Figure 1 ), we achieved with "leaky" splicing mutations (3). However, it is important consistent and reproducible results on five patients with to obtain reliable data on this issue for the design of theraidentical CFTR genotypes. pies aiming at restoring lung function by increasing the levels of normal CFTR, namely gene therapy. each on the same molecule) was combined in different ratios with a plasmid containing full-length CFTR cDNA in the following proportions: 1:1 (9 Ϫ /9 ϩ plasmid alone, no full-length CFTR); 1:2; 1:3; 1:4; 1:5; 1:6; 1:7; 1:8; 1:9; 1:10; and 1:11. Using each of these mixtures as template, PCR reactions were performed and aliquots removed at different numbers of cycles, namely: 19, 20, 21, 22, and 24. Kinetic analyses were performed by plotting the logarithm of peak areas against the respective number of cycles (data not shown) for each of the two products (exon 9 Ϫ and exon 9 ϩ ), according to the following equation: Log A ϭ [Log (1 ϩ E)] · n ϩ Log A 0 , where A 0 ϭ the starting amount of RNA; A ϭ the amount Figure 1 . Schematic representation of the control plasmid used as of amplified product (peak areas); E ϭ the amplification efficiency; external control. The plasmid contains two copies of CFTR cDNA and n ϭ the number of amplification cycles. in the region of exons 7-12 on the same molecule, one including From the slopes of lines plotting Log A (peak areas) versus n, and another excluding exon 9. Following MluI hydrolysis for linearthe number of PCR cycles (determined by linear regression from ization, the plasmid was used as a template in PCR reactions this equation), the efficiency of amplification (E) can be estimated performed in parallel with those of the patient-derived materials for each exon 9 Ϫ /exon 9 ϩ ratio as follows: linear regression of Log and using the same primers. As the two templates were initially A (peak areas) versus the number of PCR cycles (n ), for each in equimolar amounts in the plasmid, the ratio of the amounts of exon 9 Ϫ /exon 9 ϩ ratio (see Figure 3 ), allowing estimation of the the two PCR products (with and without exon 9) was used to of amplification efficiencies (E) through the equation: slope ϭ Log correct size-specific amplifications in the PCR products from pa-(1 ϩ E). tient-derived materials.
Estimate of Levels of Full-Length CFTR Transcripts primed reverse transcription (RT) reaction and PCR amplification
A schematic representation of the calculations used is shown in of regions 16-17b , were performed as previously described (5), Figure 4 . Raw data obtained from integration of peak areas (see except that the 5Ј primer was Fam-labeled. PCR amplification of Results) from independent analysis of the same patient were used region 8-10 was performed using primers: B3F: 5Ј-AATGTAAC separately to estimate levels of full-length CFTR transcripts and AGCCTTCTGGGAG-3Ј (Fam-labeled) in exon 8 (positions 1318-averaged in the end for each of the five 3272-26AϾG patients. All 1338) and C16D: 5Ј-GTTGGCATGCTTTGATGACGCTTC-3Ј in values shown are approximate averages (see Table 1 ) for exact exon 10 (positions 1685-1708). cDNA samples were heated at 94ЊC values and respective SD. Calculations made are schematically for 5 min and then subjected to amplification cycles of denaturation represented in Figure 4 and next briefly described. at 94ЊC for 1 min, primer annealing at 60ЊC for 1 min, and extension Peaks P1-P6 (see Figure 4 ) are defined as: P1, F508del, exon at 72ЊC for 2 min, followed by a final extension at 72ЊC for 30 min. 9 Ϫ ; P2, non-F508del, exon 9 Ϫ ; P3, F508del, exon 9 ϩ ; P4, nonAll PCR reactions were performed in triplicate under exactly F508del, exon 9 ϩ ; P5, normally spliced (17a) ϩ F508del; P6, alternathe same conditions but with different numbers of cycles (generally tively spliced (17a); and P deg, assumed to be degraded (not obn, n ϩ 2, and n ϩ 4) to certify that it was still in the log-phase served). (Figures 2C and 2E ). All experiments were repeated from different
Step 1: Use of plasmid to correct exon 9 Ϫ /9 ϩ unequal amplifica-RT reactions (see Table 1 , first column): three (Patient 3) or four tion. To correct peak areas (P corr ) for size-specific amplification (the other four patients). For three patients (Patients 1, 4, and 5), differences (in the region of exons 8-10), raw values for peak area measurements were from two different nasal brushings, collected integration obtained with the GeneScan software were multiplied on different occasions. PCR products were separated by polyacrylby their respective correction factors. These were estimated from amide gel electrophoresis in the ABI Prism 377 automatic sethe parallel amplification of exon 9 Ϫ /9 ϩ plasmid and found to be quencer (Applied Biosystems, Foster City, CA), and quantitative ϳ 0.4 for peaks corresponding to exon 9 Ϫ products (amplified at analysis of peaks was performed with the GeneScan software (Aphigher efficiency) and 0.6 for peaks corresponding to exon 9 ϩ plied Biosystems). This allows a direct integration of the peak area products (amplified at lower efficiency). Corrected peak areas were corresponding to the number of Fam-labeled molecules synthecalculated as follows: P1 corr ϭ P1 ϫ 0.4; P2 corr ϭ P2 ϫ 0.4; P3 corr ϭ sized by PCR to determine the relative percentages of CFTR P3 ϫ 0.6; and P4 corr ϭ P4 ϫ 0.6. mRNA specimens present.
Step 2: Estimate of percentage of transcripts relative to total To correct size-specific differences in amplification efficiency CFTR present. The second step was to estimate the percentage of for RT-PCR products obtained in the region of exons 8-10 (i.e., each of the six different CFTR transcripts present (see Figures 4 with and without exon 9) for patients, parallel PCR reactions and 5) in the patients relative to the total CFTR RNA present were performed using the same primers and a control plasmid as (Total pres ), using the corrected values determined in Step 1. Total pres template. This plasmid contains two copies of CFTR cDNA (exons can be estimated from RT-PCR amplifications in the region of 7-12) on the same molecule (see Figure 1) , one including and exons 8-10 as follows: Total pres ϭ ͚ Pn corr (n ϭ 1-4); or from another excluding exon 9. Following MluI hydrolysis for lineariza-RT-PCR amplifications in the region of exons 16-17b as follows: tion, 5 l of a 3.3 ϫ 10 Ϫ5 g/ml solution of the plasmid ‫ق(‬ 100,000 Total pres ϭ P5 ϩ P6. The percentage for each of the six different CFTR transcripts present is thus: % Pn ϭ (Pn corr / Total pres ) ϫ 100. copies) per reaction was used as a template in PCR reactions performed in parallel with samples from patients using the same
The total percentage of F508del transcripts without (P1) or with (P3) exon 9 in the five patients was estimated from the following primers and conditions. Because the plasmid has the two templates in equimolar amounts, the ratio of the amounts of the two PCR formula: % F508del ϭ (P1 corr ϩ P3 corr / Total pres ) ϫ 100 Ϸ 77.1%. Similarly, the proportion of transcripts resulting from the 3272-products (with and without exon 9) was used to correct size-specific amplifications in the PCR products from patients' samples. To 26AϾG allele that are abnormally spliced at intron 17a (alt 17a ) was estimated to be (Table 1 , second column): % alt 17a ϭ (P6 corr / determine whether amplification efficiency varies with the initial ratio of the two templates, the exon 9 Ϫ /exon 9 ϩ plasmid (1 copy Total pres ) ϫ 100 Ϸ 14.1%, and the percentage of transcripts resulting Figure 2 . Relative efficiency of amplification for exon 9 ϩ /exon 9 Ϫ products using the control plasmid. Results from electrophoresis of Fam-labeled products from PCR reactions with different number of cycles (indicated in electrophorams) and using as template 16.5 ϫ 10 Ϫ5 ng (A ) or 16.5 ϫ 10 Ϫ4 ng (B ) of the control plasmid per reaction. The peak areas shown in A and B were calculated by software integration (see Materials and Methods) and plotted on a logarithmic scale against the respective number of cycles (C and E, respectively). Also, from integration of peak areas shown in A and B, the relative percentages of products obtained with (9 ϩ ) and without (9 Ϫ ) exon 9 were estimated and plotted against the number of cycles used (D and F, respectively). By comparison of C with D, and E with F, it can be observed that the relative percentages of 9 ϩ and 9 Ϫ products are only maintained while the amplification is in the exponential phase. The scale on the left is in arbitrary units and the one above electrophorams is calibrated to base pairs (bp).
from the 3272-26AϾG allele that are normally spliced at intron mated above did not take into consideration the fact that part of these lack exon 9. Accordingly, the proportion of exon 9 Ϫ transcripts 17a (norm 17a ) was estimated from the difference between the total (100%) and the two above-mentioned percentages (of total within % norm 17a (assuming that splicings of introns 8 and 17a occur as independent events) could be estimated from the ratio of nonF508del transcripts and of abnormally spliced transcripts at intron 17a, Table 1 , third column): % norm 17a ϭ 100% -% F508del -% F508del peaks in the 8-10 region, without (P2) and with (P4) exon 9, as follows: (% norm 17a ex 9
Step 3: Estimate proportion of exon 9
Step 4: Estimate of percentage of full-length relative to total CFTR present. By using the latter value in the following system The percentage of normally spliced transcripts at intron 17a esti- ϩ and exon 9
Ϫ products with increasing exon 9 Ϫ /exon 9 ϩ ratios of initial templates. The graph is a plot of the differences in efficiency values carriers, n ϭ 30). The double of this average level is thus Total norm : for exon 9 Ϫ and exon 9 ϩ products ( y axis) for eleven different Total norm ϭ 2 ϫ wt ⇒ Total norm ϭ 2 ϫ (1.15 ϫ F508del carr ). exon 9 Ϫ /exon 9 ϩ ratios (x axis). Amplification efficiencies (E) were The amount of RNA that was assumed to be degraded (P deg ) estimated by linear regression of Log A (peak areas) versus the in the five patients (because of the stop codon in the alternative number of PCR cycles (n ): slope ϭ Log (1 ϩ E). The differences transcript) was estimated from the difference between levels of in amplification efficiencies ranged from 0.01-0.19, indicating that Total norm and Total pres : Total norm ϭ Total pres ϩ P deg ⇒ P deg ϭ the ratio of initial exon 9 Ϫ /exon 9 ϩ templates in the sample does Total norm Ϫ Total pres ⇒ P deg ϭ 2 ϫ (1.15 ϫ F508del carr ) Ϫ Total pres . not influence the amplification efficiency substantially.
Assuming that levels of F508del carr equal the levels of F508del transcripts in the 3272-26AϾG/F508del patients, i.e., using the area of the F508del peak as reference, and from Step 2 above: F508del carr ϭ F508del ϭ P3 corr ϩ P1 corr . of equations: (% norm 17a ex 9 Ϫ )/(% norm 17a ex 9 ϩ ) ϭ 1 / 17 and (% Also from
Step 2 above, the Total pres was: Total pres ϭ ͚ Pn corr norm 17a ex 9 Ϫ ) ϩ (% norm 17a ex 9 ϩ ) Ϸ 8.8%, the two following (n ϭ 1-4). And, thus: P deg ϭ 2 ϫ 1.15 ϫ [P3 corr ϩ P1 corr ] Ϫ [P1 corr ϩ values could be estimated: % norm 17a ex 9 -ϭ 0.6%; and % norm 17a P2 corr ϩ P3 corr ϩ P4 corr ]. ex 9 ϩ ϭ 8.2%. From here, we estimated the percentage of assumed degradaThe latter value is the percentage of full-length CFTR trantion that occurred for 3272-26AϾG-transcripts to be (Table 1 , scripts (i.e., normally spliced at intron 17a and containing exon 9) fourth column): % P deg ϭ P deg / Total norm x 100 Ϸ 43.5% of Total norm . relative to the total CFTR RNA present in these patients.
Step 6: Estimate percentage of transcripts relative to total in Step 5: Estimate of total CFTR RNA present in normal individunormal individuals. Levels of all transcripts present were then reals and corrections for percentage of assumed degraded trasncripts estimated, now in relation to the total CFTR mRNA in normal in 3272-26AϾG/F508del patients. To quantify the level of fullindividuals from both alleles (the total present plus the estimated length CFTR transcripts in the five 3272-26AϾG/ F508del patients assumed degraded), i.e., Total norm instead of Total pres . So, Step 2 relative to normal individuals (see Figure 4) , the amount of CFTR (see above) was repeated for Total norm and the new percentage of transcripts in the latter must be estimated. We term it "total in F508del transcripts is: % F508del ϭ (P1 corr ϩ P3 corr )/Total norm ϫ normal (wt/wt individuals)" (Total norm ). For that purpose, Total norm 100 Ϸ 43.3%. was assumed to be twice the average of wt-CFTR transcript levels Similarly, for the two types of CFTR transcripts resulting from found in F508del carriers (n ϭ 30) estimated from the F508del/wt ratio: F508del/wt Ϸ 0.87 ⇒ wt Ϸ 1.15 ϫ F508del carr (in F508del the 3272-26AϾG allele: % alt 17a ϭ (P6 corr /Total norm ) ϫ 100 Ϸ 8.2%; Figure 4 . Schematic representation of calculations made from the raw data shown in Figure 6 . For the calculations, data from independent analysis of the same patient was treated separately and averaged in the end. All values shown are approximate averages (see Table 1 for exact values Ϯ SD, and Materials and Methods for description).
functional) and part result from the 3272-26AϾG allele. 2. To determine the relative contribution of each of the alleles to the normally spliced transcripts, the relative amount of F508del versus non-F508del transcripts was determined by performing exon 8-10 amplification. 3. Amplification in the exon 8-10 region evidences exon 9 skipping; to assess exon 9 skipping, correction for unequal amplification of 9 ϩ versus 9 Ϫ products had to be introduced. 4. The combination of Steps 2 and 3 showed that most of the transcripts (77%) were from the F508del allele. 5. The combination of Steps 1 and 4 showed that ‫ق‬ 8% of full-length transcripts were from the 3272-26AϾG allele compared with F508del allele. 6. To assess the amount of wt transcripts in the patients compared with normal individuals, the relative amount of the F508del transcripts was assessed relative to transcripts from a normal allele (by using data from 30 F508del carriers). 7. Combination of Steps 5 and 6 revealed that these five patients with CF had ‫ق‬ 5% of normal levels. 
16-17b (B ). Raw data obtained from integration of these peaks
Products from the Control Plasmid ucts with (9 ϩ ) and without (9 Ϫ ) exon 9. Due to the difference in size between these products (183 nts), the amplification of exon 9 Ϫ product is expected to be more efficient than and % norm 17a ϭ 100% norm Ϫ % F508del Ϫ % alt 17a Ϫ % P deg ϭ the amplification of the exon 9 ϩ product. To determine this 100% Ϫ 43.5% Ϫ 43.3% Ϫ 8.2% Ϸ 5.0%.
difference of amplification efficiencies, we used a plasmid
Step (Table 1, 2C and 2E). It is noteworthy that the relative percentages of fifth column): % norm 17a ex 9 Ϫ Ϸ 0.3%; and % norm 17a ex 9 ϩ Ϸ the exon 9 ϩ and exon 9 Ϫ products from this external control 4.7%. The latter is the percentage of normal full-length CFTR transcripts (i.e., non-F508del transcripts, normally spliced at intron change, even invert (see graphs in Figures 2D and 2F ), when 17a and containing exon 9) relative to the estimated total amount the reaction enters the plateau phase (four lower panels in of CFTR mRNA in normal individuals. Figure 2B )-i.e., for higher numbers of amplification cycles and/or higher amount of plasmid at the beginning ( Figure  2B ). Consequently, for quantification purposes, it is impor-
Results

tant to vary the cycle number to ensure that the amplifications Summary of Quantification Process and Results
are within the exponential range ( Figures 2C and 2E ). To quantify the levels of normal CFTR transcripts in the Plotting the differences in efficiency values for exon 9 ϩ cells of the patients, two PCR reactions in the regions 8- 10 and exon 9 Ϫ products yields the graph shown in Figure 3 . and 16-17b were performed. Samples from patients are It is evident from the graph that amplification efficiencies do expected to produce four peaks in the exon 8-10 reaction not vary substantially, with increasing amounts of [Ex 9Ϫ ] 0 / (see peaks 1-4 in the "Raw data" inset of Figure 4) and [Ex 9ϩ ] 0 ratio, up to 1:11. These data indicate that the unequal two peaks in the exon 16-17b reaction (see peaks 5-6 in the ratio of initial exon 9 Ϫ /exon 9 ϩ templates (of ‫ق‬ 1:10) in inset of Figure 4 ). Based on these peak areas, calculations to the sample does not influence the amplification efficiency. obtain the levels of normal CFTR transcripts relative to a Thus, the amplification efficiencies obtained for the control normal individual (wt/wt) were made using the following plasmid (where initially the exon 9 Ϫ /exon 9 ϩ templates are general strategy (see also Figure 4 and the detailed descripin a 1:1 ratio) were used to correct values obtained experition in Materials and Methods): mentally for patients' samples. The relative intensities of 1. Amplification of exons 16-17b shows that 86% of the exon 9 ϩ and exon 9 Ϫ products from this external control CFTR transcripts are normally spliced, but part of (in the range 0.35-0.4/0.65-0.6) were therefore determined in parallel with each PCR reaction for patients' samples, these correspond to F508del (and are therefore non- full-length.
Percentage of Full-Length CFTR mRNA in the Five
Patients Relative to Total in Normal Individuals and were used to correct for their difference in amplification It is evident from peaks obtained in the analysis of exons efficiencies (see Figure 4 and note asterisk in Table 1 ).
8-10 ( Figure 6A ) that the F508del-transcripts level is significantly higher than the level of [wtϩalt 17 ] transcripts in these Transcripts from Patients with 3272-26AϾG/F508del:
patients. Therefore, we determined the ratio of F508del-tran-
Analysis of Exons 16-17b
scripts relative to a generic wt allele by analyzing nasal RT-PCR analysis in the region of exons 16-17b for tranbrushing RNA samples from F508del carriers (n ϭ 30), scripts from patients with 3272-26AϾG/F508del generated using the same method described above (RT-PCR analysis two peaks (Figure 5 ), corresponding to products from the of exons 8-10), and found it to be 0.87 Ϯ 0.06. So, contrary alternatively spliced transcript, with the expected 25 addito what is observed in patients with 3272-26AϾG/F508del tional nucleotides (lower peak on the right, 328 bp), and to ( Figure 6A ), in F508del carriers, the ratio of 0.87 Ϯ 0.06 products from the normal-sized transcripts (higher peak on indicates that the levels of F508del transcripts are consisthe left, 303 bp), respectively. The latter peak, however, tently lower than non-F508del (i.e., wt) transcripts. We becontains products both from correctly spliced transcripts lieve that the lower levels of the non-F508del transcripts from the Ϫ26 allele and F508del transcripts, as these are in patients with 3272-26AϾG/F508del must result from a indistinguishable in this region. Results from quantification dramatic decrease in the levels of alternative transcripts. of the alternative transcripts (alt 17 ) for the five patients Indeed, the latter most probably undergo degradation at analyzed are shown in Table 1 (second column) and were increased rates due the presence of a premature stop codon obtained as described in Materials and Methods (see also (5), a generally described phenomenon (7). Figure 4 ). On average, the alternative transcripts accounted
To quantify the level of full-length CFTR transcripts for 14.1 Ϯ 3.1% of the total RNA present. Similar analyses present in the patients with 3272-26AϾG/F508del in relawere made for samples from the four 3272-26AϾG-carriers tion to the total in normal individuals (i.e., with a wt/wt of the mutation (Table 2) , for which the alternative tran-CFTR genotype) we estimated the percentage of RNA that scripts accounted for an average of 10.5 Ϯ 1.2% of the total was assumed to be degraded. The latter is the difference RNA present.
between levels of expression of two generic wt-alleles (estimated from the F508del/wt ratio obtained in carriers; see Analysis of Transcripts from patients with Figure 6A ). These cormRNA degradation assumed to have occurred in patients respond, from right to left, to amplification products of the with 3272-26AϾG/F508del (see Figure 4, Step 6) to be on following transcripts: wild-type (wt) plus alternative splicing average 43.5 Ϯ 1.9% of the total in normal individuals at intron 17aϪ (alt 17 ), the latter appearing with normal size (Table 1 , fourth column). The levels of remaining normal in this region (391 bp); F508del (388 bp); wt plus alt 17 , without full-length mRNA were then re-estimated, now in relation exon 9 (208 bp); and F508del without exon 9 (205 bp). The to the total present in normal individuals (Figure 4 , Steps bands shown in Figure 5 for just one patient, are shown in 5-7). Samples from patients with 3272-26AϾG/F508del Figure 6B for the five patients analyzed in this study, and were thus found to have on average 4.7 Ϯ 0.45% of normal correspond to the correctly (left) and alternatively (right) CFTR mRNA relative to total in normal individuals (Table  spliced transcript The 3272-26AϾG mutation creates a novel acceptor in incations, i.e., regions 8-10 and 16-17b ( Figures 6A and 6B , tron 17a that competes with the normal one, producing both correctly and aberrantly spliced mRNAs (5). As with respectively), after correction for unequal amplification (re-other class I CFTR mutations (previously class V) (8-10), mined in relation to the total present) to 4.7 Ϯ 0.45% the milder clinical phenotype of patients with 3272-26AϾG (determined in relation to the total in normal individuals). (4) is due to the presence of reduced levels of functional This reduces our estimate by almost half. For determination CFTR resulting from transcripts correctly spliced at intron of full-length CFTR mRNA, we also show that it is not 17a. Here, we have quantified the levels of full-length critical in this case to deduce exon 9 Ϫ transcripts (corrected mRNA present in these patients to address the question of for amplification efficiency with plasmid), as these only acthe level of normal CFTR transcripts necessary to avoid count for ‫ق‬ 0.3% reduction in the final fraction of remaining classic CF.
transcripts in the patients with 3272-26AϾG/F508del. However, with other variants at the polymorphic region of intron Reproducibility of the Method 8 that favor exon 9 skipping, like the 5T allele (6), it may We developed and applied a sensitive and reproducible become critical to introduce this correction. method that is based on the detection and quantification Although RT-PCR is an indirect approach to determine of fluorescently-labeled molecules resulting from RT-PCR the level of full-length CFTR mRNA in patients relative amplification. The method accommodated the low number to normal individuals, it is probably the only technique that of CFTR mRNA copies present in nasal brushing samples is sufficiently sensitive for low-copy number transcripts such (11), allowing simultaneous quantitation of low-and highas CFTR. Indeed, RT-PCR has been used extensively for level transcripts. We demonstrated consistent differences estimation of CFTR transcripts by other investigators (3, in amplification efficiencies for exon 9 ϩ /exon 9 Ϫ products 6, 8, 17). However, in this study we have incorporated sev-(i.e., with 183 bp difference), by using a plasmid as control eral key controls that were not used previously and have (Figures 2A and 2B ), which to our knowledge has not been obtained consistent results from five patients. On the other used before. These results demonstrated the need to introhand, real-time PCR, which may have a number of applicaduce a correction for every PCR reaction performed to tions, is only useful to quantify differences that lead to analyze exon 9 ϩ /9 Ϫ products, and thus such a correction visible changes Ͼ 1/3 cycle. This means that for the present was used for values obtained in analysis of patient samples.
case of wt/F508del transcripts in F508del carriers, it would Our results also show the need to obtain data in the expoonly detect differences above 42%/58%, i.e., 16%. Here we nential phase of the PCR (Figure 2) , an issue that has been describe a 7% difference between F508del and wt trancontroversial (12, 13) . Therefore, we performed, for each scripts (i.e., 46.5 and 53.5%, respectively; see below), which sample analyzed, three parallel reactions differing solely in would thus will fail to be detected by real-time PCR. the number of cycles. Only those values that resulted in the same peak area ratios were used (i.e., consistent results CFTR mRNA Levels in Carriers along a semilogarithmic line; see graphs in Figure 2 ), as this proved the reaction was still in exponential phase. We also From results shown here, the aberrantly spliced transcripts demonstrated that the amplification efficiency of exon 9 ϩ present in the five patients with 3272-26AϾG/F508del correand exon 9 Ϫ RT-PCR products does not vary substantially spond on average to 14.1 Ϯ 3.1% of the total RNA present. when the initial ratio of product varies by as much as one These transcripts constitute on average 10.5 Ϯ 1.2% for the order of magnitude. This result is consistent with observafour 3272-26AϾG carriers we analyzed. This difference may tions of other authors who have shown that PCR efficiency result from variation of splicing efficiencies at the cryptic remains constant at ratios that differ by three, or even four, and normal splice acceptors in intron 17a. Because the level orders of magnitude (14-16).
of aberrant transcripts was significantly lower in parents After extensive experimentation to verify the accuracy than in their children (P Ͻ 0.05, paired Student's t test), and reproducibility of our methods, we obtained highly conwe speculate that carriers may have higher total levels of sistent results among samples from the same individual ana-CFTR mRNA than patients, due to the fact that they have lyzed on different days, and among the five patients (and four wt, not F508del, in trans with 3272-26AϾG, thus altering the carriers) analyzed. This optimized procedure distinguishes relative percentages. Indeed, we demonstrated in 30 carriers between F508del and non-F508del transcripts, thereby allowthat F508del transcripts are less abundant than wt transcripts. ing comparative analysis of the CFTR mRNA transcript levThis result was intriguing because the level of F508del tranels generated by any patients or individuals carrying F508del scripts has been shown to be the same as wt in human and any other allele.
carriers (5, [18] [19] [20] , and in the CF-F508del mouse (21) . Our finding that the F508del transcript level was consistently Limitations of the Study lower (7% on average) relative to wt is probably due to One of our objectives was to compare the levels of full-length the higher sensitivity of the method we employed. The transcripts present in these patients relative to normal indibiologic reason for this difference is not understood at this viduals. Because quantification methods like Northern blotpoint, as it may result from either diminished transcription ting or RNAse-protection assay (RPA) are not possible for (the F508del allele may be in cis with a less efficient variant CFTR transcripts because of their low abundance in native of the promoter than wt) or enhanced degradation of the tissues (11), we used an indirect approach. The importance mutant transcripts. The CF-F508del mouse model, described of taking into account transcript degradation, assumed to to have equal levels of both transcripts, was produced by occur for alternative transcripts, is illustrated by the fact introducing the F508del mutation into a normal CFTR gene that the level of full-length CFTR mRNA in patients with 3272-26AϾG/F508del decreases from 8.2 Ϯ 0.84% (deter- (21) , an argument that favors the first hypothesis.
Comparisons with Other Studies and Implications function and pancreatic involvement, are attenuated by comparison to patients with two severe mutations (4). It for CF Therapy should, however, be kept in mind that 5% is not enough Previous reports describing CFTR RNA quantifications did to avoid the complications of CF, indicating that this threshnot correct for size-specific differences in amplification effiold will probably have to be surpassed in therapeutic apciency, and so comparisons were made between PCR prodproaches aimed at increasing CFTR levels. ucts with and without exon 9 (6), or between products differing 84 bp in size (8). This could have led to underesti-
